Wen, Z., Guo, Y., Liu, S., Yang, C., Wang, C., Zhang, R., Yunfei, W., Yanan, S., Li, J. (2026). Cost-effectiveness of first-line osimertinib plus chemotherapy versus amivantamab plus lazertinib for advanced EGFR -mutant NSCLC in the US and China.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.e23169